Literature DB >> 18384521

Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus.

Nathalie C Leite1, Gil F Salles, Antonio L E Araujo, Cristiane A Villela-Nogueira, Claudia R L Cardoso.   

Abstract

BACKGROUND/AIMS: Diabetic patients have an increased prevalence and severity of non-alcoholic fatty liver disease (NAFLD). We aimed to investigate the prevalence and the factors associated with the presence of ultrasonographic NAFLD in type-2 diabetic individuals.
METHODS: In a cross-sectional design study, 180 type-2 diabetic patients were submitted to a complete clinical and laboratory evaluation and abdominal ultrasonography for NAFLD detection and grading. Statistical analysis included bivariate tests, analysis of variance (anova, for increasing severity of steatosis) and multivariate logistic regression.
RESULTS: The prevalence of ultrasonographic NAFLD was 69.4% [95% confidence interval (CI): 58.3-82.7%]. Patients with NAFLD were more obese, had a higher waist circumference and serum triglyceride and alanine aminotransferase (ALT) levels than those without steatosis. Neither diabetic degenerative complication, nor glycaemic control was associated with liver steatosis. On multivariate analysis, a high serum triglycerides level [>2.82 mmol/L, odds ratio (OR): 3.7-4.1, 95% CI: 1.2-13.3] and a high-normal ALT level (> or =40 U/L, OR: 2.5-2.7, 95% CI: 1.2-5.9) were independently associated with hepatic steatosis, together with either the presence of obesity (OR: 7.1, 95% CI: 3.0-17.0) or of increased waist circumference (OR: 4.8, 95% CI: 1.9-12.2).
CONCLUSIONS: Type-2 diabetic patients have a high prevalence of ultrasonographic NAFLD and its presence is associated with obesity, mainly abdominal, hypertriglyceridaemia and high-normal ALT levels. Non-alcoholic fatty liver disease in diabetic patients may develop and progress independent of the diabetes progression itself.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18384521     DOI: 10.1111/j.1478-3231.2008.01718.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  159 in total

Review 1.  Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment.

Authors:  Nathalie C Leite; Cristiane A Villela-Nogueira; Claudia R L Cardoso; Gil F Salles
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 2.  Modern approach to the clinical management of non-alcoholic fatty liver disease.

Authors:  Maria Del Ben; Licia Polimeni; Francesco Baratta; Daniele Pastori; Lorenzo Loffredo; Francesco Angelico
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

3.  Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.

Authors:  Yuya Seko; Yoshio Sumida; Kazuyo Sasaki; Yoshito Itoh; Hiroaki Iijima; Toshio Hashimoto; Shinichi Ishii; Nobuya Inagaki
Journal:  J Gastroenterol       Date:  2017-07-01       Impact factor: 7.527

4.  Hepatocyte-specific depletion of ubiquitin regulatory X domain containing protein 8 accelerates fibrosis in a mouse non-alcoholic steatohepatitis model.

Authors:  Norihiro Imai; Michitaka Suzuki; Yoji Ishizu; Teiji Kuzuya; Takashi Honda; Kazuhiko Hayashi; Masatoshi Ishigami; Yoshiki Hirooka; Tetsuya Ishikawa; Hidemi Goto; Toyoshi Fujimoto
Journal:  Histochem Cell Biol       Date:  2017-04-18       Impact factor: 4.304

5.  A Mitochondrial VDAC1-Based Peptide Greatly Suppresses Steatosis and NASH-Associated Pathologies in a Mouse Model.

Authors:  Srinivas Pittala; Yakov Krelin; Yael Kuperman; Varda Shoshan-Barmatz
Journal:  Mol Ther       Date:  2019-07-12       Impact factor: 11.454

6.  Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease.

Authors:  Licia Polimeni; Daniele Pastori; Francesco Baratta; Giulia Tozzi; Marta Novo; Roberto Vicinanza; Giovanni Troisi; Gaetano Pannitteri; Fabrizio Ceci; Laura Scardella; Francesco Violi; Francesco Angelico; Maria Del Ben
Journal:  Intern Emerg Med       Date:  2017-09-12       Impact factor: 3.397

Review 7.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

8.  Nonalcoholic fatty liver disease: a frequent condition in type 2 diabetic patients.

Authors:  Alexandra Sima; Romulus Timar; Adrian Vlad; Bogdan Timar; Mihaela Rosu; Isabel Dan; Roxana Sirli; Alina Popescu; Ioan Sporea
Journal:  Wien Klin Wochenschr       Date:  2014-03-21       Impact factor: 1.704

9.  Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients.

Authors:  Jang Hyun Koh; Young Goo Shin; Soo Min Nam; Mi Young Lee; Choon Hee Chung; Jang Yel Shin
Journal:  Diabetes Care       Date:  2008-10-03       Impact factor: 17.152

10.  Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease.

Authors:  Jung Won Yun; Yong Kyun Cho; Jung Ho Park; Hong Joo Kim; Dong Il Park; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim
Journal:  Liver Int       Date:  2009-04       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.